JBIO
Price
$21.34
Change
+$0.11 (+0.52%)
Updated
Aug 21 closing price
Capitalization
1.36B
85 days until earnings call
Intraday BUY SELL Signals
MBX
Price
$66.33
Change
-$0.02 (-0.03%)
Updated
Aug 21 closing price
Capitalization
3.19B
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JBIO vs MBX

JBIO vs MBX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JBIO vs. MBX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JBIO is a Hold and MBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (JBIO: $21.34 vs. MBX: $66.33)
Brand notoriety: JBIO and MBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JBIO: 43% vs. MBX: 43%
Market capitalization -- JBIO: $1.36B vs. MBX: $3.19B
JBIO [@Biotechnology] is valued at $1.36B. MBX’s [@Biotechnology] market capitalization is $3.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JBIO’s FA Score shows that 1 FA rating(s) are green whileMBX’s FA Score has 1 green FA rating(s).

  • JBIO’s FA Score: 1 green, 4 red.
  • MBX’s FA Score: 1 green, 4 red.
According to our system of comparison, MBX is a better buy in the long-term than JBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JBIO’s TA Score shows that 4 TA indicator(s) are bullish while MBX’s TA Score has 2 bullish TA indicator(s).

  • JBIO’s TA Score: 4 bullish, 6 bearish.
  • MBX’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, both JBIO and MBX are a bad buy in the short-term.

Price Growth

JBIO (@Biotechnology) experienced а -13.64% price change this week, while MBX (@Biotechnology) price change was -3.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

JBIO is expected to report earnings on Nov 16, 2026.

MBX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MBX($3.19B) has a higher market cap than JBIO($1.36B). MBX YTD gains are higher at: 110.304 vs. JBIO (38.302). MBX has higher annual earnings (EBITDA): -98.56M vs. JBIO (-133.57M). MBX has more cash in the bank: 440M vs. JBIO (311M). MBX has less debt than JBIO: MBX (555K) vs JBIO (679K). JBIO (0) and MBX (0) have equivalent revenues.
JBIOMBXJBIO / MBX
Capitalization1.36B3.19B42%
EBITDA-133.57M-98.56M136%
Gain YTD38.302110.30435%
P/E RatioN/A3.88-
Revenue00-
Total Cash311M440M71%
Total Debt679K555K122%
TECHNICAL ANALYSIS
Technical Analysis
JBIOMBX
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
77%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 10 days ago
90%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
JBIO
Daily Signal:
Gain/Loss:
MBX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PTEU34.600.29
+0.84%
Pacer Trendpilot™ European ETF
VFQY178.221.34
+0.76%
Vanguard US Quality Factor ETF
HWSM31.960.22
+0.68%
Hotchkis & Wiley SMID Cap Divers Val Fd
ELD29.110.10
+0.33%
WisdomTree Emerging Markets Lcl Dbt ETF
UTG38.46-0.19
-0.49%
Reaves Utility Income Fund